Locally advanced or metastatic solid tumor ovarian, testicular or other Claudin 6+ cancers
Measurable or evaluable disease, per RECIST v1.1
Eastern Cooperative Oncology Group (ECOG) performance status 0-1
Adequate organ function
You may not be if
Active CNS involvement
Malignancy diagnosis other than the disease under study within 2 years prior to the first dose of study drug.
Presence of uncontrolled ascites
Toxicity related to prior anticancer therapy that has not returned to Grade ≤1 or baseline levels
Clinically significant pulmonary compromise
Active autoimmune disease within 12 months prior to first dose of study drug.
Female participant who is pregnant, breastfeeding, or plans to become pregnant or male participant who plans to father a child either while enrolled or within 90 days after the final administration of study drug.
